Eluminex Acquires Synthetic Cornea Product in $108 Million Agreement

Eluminex Biosciences ( Suzhou ), an ophthalmology biotech, in-licensed global rights to a biosynthetic cornea developed by FibroGen. The synthetic cornea, which is intended to treat corneal blindness, is derived from recombinant human collagen Type III. Eluminex will make an $8 million upfront payment and will pay up to $64 million in milestones for the biosynthetic cornea program and $36 million in commercial milestones for the next non-corneal collagen III product. More details.... Stock Symbol: (NSDQ: FGEN) Share this with colleagues: // //